Market Place
Sourcing Support
Alzheon Names Muneer Satter To Board As Financial Executive
07 Jan 2025 //
BUSINESSWIRE
Alzheon Publishes APOLLOE4 Trial Design For Alzheimer`s
18 Sep 2024 //
BUSINESSWIRE
Alzheon To Present ALZ-801 Trial Results At Alzheimer`s Conference
23 Jul 2024 //
BUSINESSWIRE
Alzheon Appoints Gino Santini To Board Of Directors
12 Jun 2024 //
BUSINESSWIRE
Alzheon Raises $100M Series E For Alzheimer`s Drug Development
12 Jun 2024 //
BUSINESSWIRE
Alzheon Doses First Patient In APOLLOE4 Extension, Launches Phase 2
30 Apr 2024 //
BUSINESSWIRE
Alzheon’s oral anti-amyloid drug has to be first oral A?-targeting approved
18 Apr 2024 //
ECONOMICTIMES
Alzheon Announces that U.S. Patent Office Invalidating ALZ-801/Valiltramiprosate
08 Apr 2024 //
BUSINESSWIRE
Peer-Reviewed Scientific Proposes Unifying Single Toxin Theory for AD and ND
26 Mar 2024 //
BUSINESSWIRE
Alzheon to Present Clinical Results from Pivotal Program of Oral ALZ-801
27 Feb 2024 //
BUSINESSWIRE
Dr. Martin Tolar Awarded Eliška and Zdeněk Strmiska Award from Alzheimer’s Foundation
03 Jan 2024 //
BUSINESSWIRE
Dr. Martin Tolar to Present ALZ-801 Alzheimer’s Treatment Program
03 Jan 2024 //
BUSINESSWIRE
Alzheon Promotes Glenn E. Pauly to Chief Commercial Officer
05 Dec 2023 //
BUSINESSWIRE
Alzheon CEO Dr. Martin Tolar to Discuss Results from Phase 2 Biomarker Study
31 Oct 2023 //
BUSINESSWIRE
Alzheon to Present Clinical Results from Pivotal Program of Oral ALZ-801
17 Oct 2023 //
BUSINESSWIRE
Alzheon To Present Pivotal Program of Oral ALZ-801/Valiltramiprosate
26 Sep 2023 //
BUSINESSWIRE
Alzheon Reports IClinical Benefits in Phase 2 Trial of Oral ALZ-801
13 Sep 2023 //
BUSINESSWIRE
Alzheon to Present Characteristics from APOLLOE4 Phase 3 Trial of ALZ-801
11 Jul 2023 //
BUSINESSWIRE
Alzheon to Present Baseline Imaging from APOLLOE4 Ph3 Trial of Oral Tab ALZ-801
18 Apr 2023 //
BUSINESSWIRE
Alzheon Announces Early Completion of Enrollment of APOLLOE4 Phase 3 Trial
06 Dec 2022 //
BUSINESSWIRE
Alzheon to Present Clinical Effects with Oral ALZ-801 (Valiltramiprosate)
22 Nov 2022 //
BUSINESSWIRE
Alzheon Appoints Glenn Pauly as Head of Commercial
20 Sep 2022 //
FIRSTWORLDPHARMA
Alzheon Reports Brain Preservation for Treatment in PII Trial of ALZ-801
20 Sep 2022 //
BUSINESSWIRE
Alzheon`s Alzheimer`s asset axes brain injury biomarker in trial
20 Sep 2022 //
FIERCEBIOTECH
Alzheon to Present Industry-Leading PII Biomarker and Clinical Data with ALZ-801
26 Jul 2022 //
BUSINESSWIRE
Alzheon to Present ALZ-801 Oral Tablet Program Update
07 Jun 2022 //
BUSINESSWIRE
Alzheon Appoints Susan Flint as VP of Clinical Operations and many more
14 Apr 2022 //
BUSINESSWIRE
Alzheon Announces Closing of Oversubscribed $50M Series D Financing Round
14 Apr 2022 //
BUSINESSWIRE
Alzheon to Present ALZ-801 (Valiltramiprosate) Phase 3 Program Update
08 Mar 2022 //
BUSINESSWIRE
Alzheon Shows Disease Modifying Effects from Phase 2 Biomarker Trial of ALZ-801
08 Feb 2022 //
BUSINESSWIRE
Alzheon to Present New Data from Ongoing Phase 2 Biomarker Trial of ALZ-801
01 Nov 2021 //
BUSINESSWIRE
Alzheon Appoints Adem Albayrak as Head of Operations and more
13 Sep 2021 //
BUSINESSWIRE
Publication Shows Central Role of Neurotoxic Soluble Amyloid Oligomers
23 Jun 2021 //
BUSINESSWIRE
Alzheon Completes Patient Enrollment in Phase 2 Biomarker Trial of ALZ-801
23 Jun 2021 //
BUSINESSWIRE
Alzheon CEO Presents Overview of Oral Anti-Amyloid ALZ-801
24 Feb 2021 //
YAHOO
Alzheon CEO Presents Overview of Oral Anti-Amyloid ALZ-801
24 Feb 2021 //
BUSINESSWIRE
Alzheon Announces Dosing of First Patient in ALZ-801 Phase 2 Biomarker Study
27 Oct 2020 //
BIOSPACE
Alzheon Announces Dosing of First Patient in ALZ-801 Phase 2 Biomarker Study
27 Oct 2020 //
BUSINESSWIRE
